Evidence map›Paper›PMID 37162948›Full record

ArticlemedRxiv : the preprint server for health sciences2023

Development and application of an algorithm for statin-induced myopathy based on electronic health record-derived structured elements.

Akinyemi Oni-Orisan, Meng Lu, Jonathan A Peng, Ronald M Krauss, Carlos Iribarren, Marisa W Medina

Open access · greenAbstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Akinyemi Oni-OrisanDepartment of Clinical Pharmacy, Institute for Human Genetics, University of California San Francisco, San Francisco CA 94143, USA.
Meng LuKaiser Permanente Division of Research, 2000 Broadway, Oakland, CA 94612, USA.
Jonathan A PengDepartment of Cardiology, Kaiser Permanente, Santa Rosa, CA 95403, USA.
Ronald M KraussDepartment of Medicine, Department of Pediatrics, University of California San Francisco, Oakland CA 94609, USA.
Carlos IribarrenKaiser Permanente Division of Research, 2000 Broadway, Oakland, CA 94612, USA.
Marisa W MedinaDepartment of Pediatrics, University of California San Francisco, Oakland CA 94609, USA.
University of California, San Francisco · USKaiser Permanente · USKaiser Permanente Santa Rosa Medical Center · US

Funding

Pharmacogenomics of Statin TherapyP50GM115318 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI REUE, KAREN · 2015 to 2019
$14.0M
Characterization of response to lipid-modifying regimens for atherosclerotic cardiovascular disease using electronic health recordsK01HL143109 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ONI-ORISAN, AKINYEMI · 2018 to 2022
$887k
NHLBI NIH HHS K01 HL143109NIGMS NIH HHS P50 GM115318
6 · The paper itself

Abstract

Objective: Considering the non-specific nature of muscle symptoms, studies of statin-induced myopathy (SIM) in electronic health records require accurate algortihms that can reliably identify true statin-related cases. However, prior algorithms have been constructed in study populations that preclude broad applicability. Here we developed and validated an algorithm that accurately defines SIM from electronic health records using structured data elements and conducted a study of determinants of SIM after applying the algorithm. Materials and Methods: We used electronic records from an integrated health care delivery system (including comprehensive pharmacy dispensing records) and defined SIM as elevated creatine kinase (CK) ≥4 x upper limit of normal. A diverse cohort of participants receiving a variety of statin regimens met the criteria for study inclusion. Results: We identified multiple conditions strongly associated with elevated CK independent of statin use. A 2-step algorithm was developed using these all-cause conditions as secondary causes (step 1) along with evidence of a statin regimen change (step 2). We identified 1,262 algorithm-derived statin-induced elevated CK cases. Gold standard SIM cases determined from manual chart reviews on a random subset of the all-cause elevated CK cases were used to validate the algorithm, which had a 76% sensitivity and 77% specificity for detecting the most certain cases. Pravastatin use was associated with a 2.18 odds (95% confidence interval 1.39-3.40, P=0.0007) for statin-induced CK elevation compared to lovastatin use after adjusting for dose and other factors. Conclusions: We have produced an efficient, easy-to-apply methodological tool that can improve the quality of future research on statin-induced myopathy.

Indexed as

Adverse drug reactioncreatine kinaseEHRmyotoxicityreal world evidence

Identifiers

PMID37162948
PMCPMC10168492
OpenAlexW4366997543

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.